Vor Biopharma is a clinical-stage biotechnology company focused on autoimmune disease therapies. Its lead asset is telitacicept, a dual BAFF/APRIL-targeting fusion protein advanced for conditions such as generalized myasthenia gravis and Sjögren’s disease. The company aims to rebalance pathogenic autoantibody-driven immunity rather than treat a broad range of unrelated indications. Development and potential commercialization of this modality define its current profile, with limited product revenue typical of late clinical biotechs.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -1,573.7 | — |
| Q3 2025 | 0 | — | -812.7 | — |
| Q4 2025 | 0 | — | 1,722.9 | — |
| Q1 2026 | 0 | — | -219.6 | — |
| Q2 2026 | 0 | — | -62.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Castle Biosciences, Inc. (CSTL), Evolution Metals & Technologies Corp. (EMAT), CeriBell, Inc. (CBLL), Sigma Lithium Corporation (SGML), NB Bancorp, Inc. (NBBK), Seaport Therapeutics, Inc. (SPTX)